We are live on ! Find out more
BHC icon

Bausch Health

8.22 USD
-0.34
3.97%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
8.21
-0.01
0.12%
1 day
-3.97%
5 days
-1.44%
1 month
28.04%
3 months
20.7%
6 months
49.45%
Year to date
14.01%
1 year
37%
5 years
-67.82%
10 years
-55.2%
 

About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Employees: 20,300

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 29.2%
Neutral 66.7%
Negative 4.2%
Neutral
PRNewsWire
3 days ago
Bausch Health's Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide
Milestone underscores more than two decades of innovation and continued global adoption of Solta Medical's aesthetic technologies LAVAL, QC, Nov. 20, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, today announced that Solta Medical has surpassed 10 million treatments worldwide across its aesthetic technology portfolio, marking a significant milestone in the company's history. As the manufacturer of leading aesthetic technologies, including Thermage®, Fraxel®, Clear + Brilliant® Touch, and VASERlipo®, Solta Medical has helped advance medical aesthetics through science-driven innovation.
Bausch Health's Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide
Positive
Zacks Investment Research
10 days ago
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Neutral
PRNewsWire
16 days ago
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
Neutral
Zacks Investment Research
18 days ago
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
Positive
Zacks Investment Research
19 days ago
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
24 days ago
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
Neutral
Seeking Alpha
24 days ago
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
Positive
Zacks Investment Research
24 days ago
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
24 days ago
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
Neutral
MarketBeat
24 days ago
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
Price charts implemented using Lightweight Charts™